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Abstract 
Systemic lupus erythematosus (SLE) is a heterogeneous disease that can affect multiple organs.  
A hallmark of this disease, like for other autoimmune diseases, is the presence of large amounts 
of autoantibodies.  As such SLE is considered to be a B cell disease perpetuated by the expansion 
of autoreactive T and B cells.  The T cells involved have long been considered to be Th1 and 
Th17 cells as these potent pro-inflammatory cells can be found in the tissues of SLE patients.  
Recent advances point to a role for the Th2 environment in contributing to SLE through 
promotion of autoantibody production.  Here we describe the recent work focusing on 
autoreactive IgE and the activation of basophils as promoting the production of autoantibodies in 
SLE.  The findings, both in a mouse model of SLE and in human SLE subjects, support the 
concept that the activation of the basophil by autoreactive IgE-containing immune complexes 
serves to amplify the production of autoantibodies and contributes to the pathogenesis of disease.  
We propose that therapeutic targeting of this amplification loop by reducing the levels of 
circulating autoreactive IgE may have benefit in SLE.  
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Introduction 
Systemic Lupus Erythematosus (SLE) is a complex, multifactorial, autoimmune disease that can 
affect multiple organs [1].  SLE is heterogeneous both in symptoms and in which target organs 
may be involved with damage occurring in the central nervous system (CNS), kidney, heart, 
skin, joints and vessels.  It is well recognized that tissue damage is associated with immune 
complexes deposition and chronic inflammation [1].  The immune complexes formed are 
generally comprised of auto-reactive antibodies, auto-antigens and complement components [1].  
In SLE, most of the auto-reactive antibodies are raised against nuclear components.  This self-
immunization has at its origin the loss of tolerance due to environmental and/or genetic factors 
that promote cell death and release of nucleosomal components that are a source of self-antigens.  
The loss in tolerance is exacerbated through increased numbers of self-reactive T cells and B 
cells, ultimately leading to the persistent and prolific production of autoantibodies against double 
stranded DNA (dsDNA), nucleosomal proteins (Ro, La, Sm), neurotransmitter receptors (N 
methyl D aspartate (NMDA) receptors), plasma membrane components (phospholipids), 
cytoskeleton associated proteins (α-actinin), or complement components (C1q) [1].  These auto-
reactive antibodies (which can be of IgA, IgM, and IgG subclasses) form circulating immune 
complexes (CIC) in the periphery when they encounter their self-target [1].  They can deposit 
into organs, irrespective of the particular isotype of auto-reactive antibody.  As a direct 
consequence, chronic inflammation (with inflammatory cells infiltrates and pro-inflammatory 
cytokine production) is established leading to symptoms of disease and tissue damage: i.e, 
cognitive impairment and hippocampal damage in the CNS, nephritis in the kidney, skin rashes, 
arthritis in the joints and fetal heart block in pregnant women [1].  
As many autoimmune diseases, SLE has no specific treatment nor early diagnostic tools 
allowing disease prevention, disease control or definitive healing.  Strong immunosuppressive 
therapy is still the preferred manner to temporarily silence the disease, with all of its 
accompanying side effects [1].  SLE affects about 1 person in 2,500 in northern Europe and over 
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1 in 1,000 in the United States, thus lupus prevention and treatment is an important international 
challenge.  Environmental and/or genetic factors as contributors to development or severity of 
disease are evident but their roles are poorly understood.  For example, approximately 90% of 
SLE patients are child-bearing aged women and incidence of disease is 10 fold higher in African 
American women than in women of northern European.  In some geographic areas within the 
US, the disease can affect 1 out of every 200 people [1].  Thus, how genetics and environment 
contribute remains an enigma whose resolution may well advance treatment of this disease. 
The immunological basis of SLE has allowed considerable exploration on the factors and 
types of immune cells involved in its pathogenesis.  Animal models (mainly mouse models with 
some features of human disease) have allowed the study of the contribution of particular T cell 
subsets, B cells, monocytes, and dendritic cells in the development of lupus-like disease ([2]).  
These models have been useful in defining that the pathogenesis of disease lies in the loss of 
tolerance in the T and B cell compartments [2,3].  B cells themselves were shown to be essential 
for manifestation of the disease [4].  Studies in human SLE subjects have also confirmed that 
dysregulation of tolerance in these cellular compartments is a hallmark of disease [5].  These 
advances in an immunological understanding of disease has led to a number of clinical trials 
aiming to disrupt the production of auto-antibodies by targeting B cells [6-8].  Interestingly, 
depletion of B cells with an anti-CD20 monoclonal antibody (Rituximab, Rituxan®) did not 
show increased efficacy in alleviating refractory disease in a phase III clinical trial [8].  In 
contrast, clinical trials aiming to disrupt B cell activation by B cell activating factor (BAFF) 
through the use of another monoclonal antibody (Belimumab, Benlysta®) showed more 
encouraging results [7,8].  However, it should be noted that the criterion used for determining 
efficacy in these two clinical trials were markedly different.  BAFF (or Blys, for B lymphocyte 
stimulator) is a member of the TNF ligand superfamily.  This cytokine is able to activate B cells 
to mature towards antibody-secreting plasma cells and to proliferate.  This cytokine is found in 
higher titers in the periphery of SLE patients [9].  Thus, while some of these trials have shown 
some promise, it is clear that such strategies are not a panacea for all individuals with SLE and 
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continued efforts towards gaining a further understanding of the contributing factors in SLE are 
essential.  
Herein, we present novel insights on the underlying mechanisms contributing to SLE 
pathogenesis.  Whereas the involvement of Th1 and Th17 cells and cytokines in SLE are well 
documented [10,11], the contribution of the Th2 environment was poorly understood.  Our recent 
work has demonstrated that basophils and auto-reactive IgE play a role in SLE pathogenesis 
[12].  This finding, and the demonstrated interruption of SLE pathogenesis through inhibiting 
production of IgE or activation of basophils in a mouse model of spontaneous SLE, provides a 
novel strategy with therapeutic promise in disease intervention. 
 
SLE: a B cell disease that includes IgE autoantibody production 
As mentioned in the introduction, most of the pathologic features of SLE are linked to the levels 
and types of auto-reactive antibodies present in the serum of SLE patients.  Disease activity is 
associated with the levels of autoantibodies.  These auto-reactive antibodies are produced by 
plasma cells derived from auto-reactive B cells.  Minimal data is available on how tolerance is 
broken leading to the accumulation of auto-reactive lymphocytes.  However, there is 
considerable evidence that the innate immune response is somehow involved [1].  The presence 
of an interferon alpha (IFNα) signature in a large proportion of SLE patients corroborates the 
activation of an innate immune response [13].  Studies in both mouse models and human subjects 
also suggest a defect in T regulatory cells [14,15].  Nonetheless, it is well accepted that SLE is 
primarily a B cell disease and that escape from negative selection of auto-reactive B cells is the 
key element leading to the production of auto-reactive antibodies that results in the presence of 
circulating immune complexes able to deposit in the targeted organ [1]. 
While autoantibody involvement in SLE pathogenesis is well documented, the relevance 
of antibody isotypes is not well understood.  It is widely accepted that circulating immune 
complexes and immune complexes deposits contain IgM, IgG and IgA auto-reactive antibodies 
[1].  Several studies [16-18] have also shown the presence of auto-reactive IgE in such immune 
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complexes.  While IgG autoantibodies have been intimately linked to tissue damage and the 
pathology of SLE, there is also evidence for the involvement of IgM and IgA in lupus nephritis 
[1,19,20].  In some SLE patients high levels of IgE have been observed [18,21], whereas in 
others IgE levels were normal.  Interestingly, whether allergy is associated with lupus is 
controversial and while a few reports [22] have linked these diseases there is also considerable 
evidence to the contrary [18,23,24].  Thus, little was known about the role of IgE in SLE.  As we 
describe in more detail below, a key findings is the presence of auto-reactive IgE in a mouse 
model of spontaneous SLE and in a large proportion of SLE patients [12].  Importantly, the 
levels of auto-reactive IgE was associated with disease severity.  This unexpected finding 
provided a strong impetus for deciphering the role of auto-reactive IgE in lupus. 
 
The Basophil 
Basophils are rare immune cells (<1% of circulating leukocytes) well known for their 
involvement in allergic reactions and parasite infections [25] .  Their ability to produce large 
amounts of Th2 promoting cytokines such as interleukin 4 (IL-4) and thymic stromal 
lymphopoietin (TSLP) provides them the ability to serve as immune regulators, able to influence 
T and B cells to promote and produce antibodies, respectively [25].  Recent studies showed that 
basophils are able to regulate humoral memory responses by producing IL-4 and IL-6 [26].  They 
were also shown to induce Th2 differentiation of naïve CD4 T cells in vivo [27-30], present 
antigen as professional antigen presenting cells (APCs) through expression of MHC class II [31-
33], to promote plasma cells survival [12,34], and to organize the recruitment of other immune 
cells in an IgE-mediated chronic allergic inflammation model [35].  Whether basophils 
exclusively play these roles is uncertain.  For example, basophil-deficient mice were recently 
shown to mount normal Th2 responses as well as normal humoral responses [36] suggesting that 
basophils are dispensable for these responses.  However, one must be careful in overinterpreting 
experiments based on the use of a particular challenge or model.  On the other hand, it is also 
likely that basophils do not replace dendritic cells as initiators of Th2 responses and, in fact, 
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evidence has been presented for collaboration of these two cell types in initiating Th2 responses 
[37].  Thus, it is likely that the basophil’s role as an immunoregulatory cell may well be context 
dependent, where in some settings it may play a dominant role and in others it may be less 
important.   
 
Lyn Kinase: a molecular rheostat in the development of lupus     
Lyn is a Src family tyrosine kinase (SFK) that functions to promote or inhibit molecular signals 
downstream of multiple receptors including cytokine receptors (such as IL-4R or IL-3R), growth 
factor tyrosine kinase receptors (such as Kit or CD117) or Fc receptors (such as the high affinity 
IgE receptor, FcεRI).  This kinase is expressed in the hematopoietic compartment [38] but is not 
known to be expressed by T cells [39].  B cells express Lyn kinase and it serves as a key 
component of the B cell antigen receptor (BCR) through its ability to phosphorylate this receptor 
and initiate signal transduction upon BCR engagement [40].  Interestingly, however, mice 
deficient in Lyn kinase show a B cell hyperreactivity to IL-4 and CD40L stimulation [41,42], 
whereas BCR activation of Lyn-deficient B cells is impaired.  Interestingly, mast cells [43-45] 
and monocytes [46](and  more recently basophils [30]) from Lyn deficient mice have also been 
shown to be hyperreactive to various stimuli, thus demonstrating that Lyn kinase plays an 
important role in controlling cell homeostasis.  It is now well recognized that this is mediated, to 
a large extent, through the requirement for Lyn kinase in the phosphorylation and activation of 
various phosphatases [38] whose activity is important in controlling immune cell homeostasis.  
Importantly, too much Lyn activity also has undesired immunological consequence and has been 
shown to promote uncontrolled monocytic proliferation and tumor development [47] as well as 
mast cell activation [44].  Thus, the amount of Lyn kinase activity must be well controlled and it 
appears that Lyn kinase serves as a rheostat in controlling immune cell homeostasis.  
As they age (about 12-14 weeks of age), Lyn kinase deficient mice begin to produce 
auto-reactive antibodies against nuclear components, such as double stranded DNA and other 
anti-nuclear antigens.  These mice develop an autoimmune phenotype with some similarities to 
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human lupus including the development of lupus nephritis.  As early as 20 weeks of age, Lyn 
deficient mice show glomerular deposits of anti-dsDNA IgG antibodies and circulating immune 
complexes.  They develop impaired renal function and ultimately die of renal failure [48,49].  
Interestingly, it has been shown that Lyn expression is decreased in peripheral B cells of some 
SLE patients [50] and recently a single nucleotide polymorphism in the promoter region of the 
Lyn gene was linked with SLE patients of northern European heritage [51].  Of particular note, 
the described polymorphism was associated with autoantibody production.  Thus, while yet 
undefined, the role of this Lyn polymorphism in the development of SLE is of considerable 
interest.  Nonetheless, in animal models, the role of Lyn in controlling B cell responsiveness (and 
thus antibody production) is well appreciated; less is known about its contributory role in other 
cellular compartments that may also contribute in the pathogenesis of SLE.   
 
Lyn kinase and basophils: Regulation of the Th2 environment 
It has long been recognized that the high affinity IgE receptor (FcεRI) requires the activity of 
Lyn kinase to transmit signals that promote the effector responses of mast cells and basophils 
[52].  This kinase phosphorylates FcεRI and initiates signal transduction, but it also has both 
positive and negative regulatory roles downstream of FcεRI phosphorylation [44].  Multiple 
studies have demonstrated that Lyn kinase has a dominant role as a negative regulator of cellular 
homeostasis [38] and in mast cells its absence was shown to cause enhanced mast cell 
degranulation and cytokine production [44].  Strikingly, Lyn-/- mice developed an early life 
atopic-like allergic phenotype where high levels of IgE are produced and circulating histamine 
can be detected as well as an eosinophilia [43,44].  Additional studies demonstrated that these 
mice had an exacerbated response to challenge in an asthma model [53] and were generally 
hypersensitive to a Th2 challenge but also mounted a Th2 response to normally innocuous 
substances [30].  A significant proportion of CD4+ T cells from the spleen of Lyn-/- mice 
spontaneously produced IL-4.  This Th2 bias was dependent on IL-4 and IgE since the deletion 
of these genes in the context of Lyn-/- mice completely ablated their Th2 skewing [30]. 
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Since Lyn is not expressed in T cells, our initial bias was that mast cells might be driving 
this unexpected Th2 skewing in Lyn-/- mice.   To test this possibility, mast cell deficient mice 
(Kitw-sh/w-sh) were crossed to Lyn-/- mice.  However, the resulting mice (Kitw-sh/w-sh Lyn-/-) showed 
no alteration of the Th2 bias [30].  This meant that the Th2 bias was initiated by another cell type 
able to produce substantial amounts of IL-4 to induce naïve CD4+ T cells to differentiate to Th2 
cells.  Analysis of other cell types demonstrated that Lyn-/- mice had a peripheral basophilia (up 
to 4 times the amount of circulating basophils when compared to wild type (WT) mice).  In 
addition, Lyn-/- basophils could produce high levels of IL-4 being hyperresponsive to FcεRI 
stimulation.  To assess the role of these basophils in causing Th2 skewing in the absence of Lyn 
kinase, we first activated basophils in vivo in the Kitw-sh/w-sh Lyn-/- double deficient mice by FcεRI 
stimulation.  In the absence of mast cells or immune challenges, basophils are the principal cells 
that express FcεRI in the mouse.  FcεRI stimulation of Kitw-sh/w-sh Lyn-/- double deficient mice 
revealed a marked increase in the Th2 skewing of these mice with as much as 25% of the CD4+ 
T cells in the spleen producing IL-4.  The inverse experiment where basophils were depleted 
from Lyn-/- mice with a monoclonal antibody (clone MAR-1, anti-FcεRIα [29]) showed a 
complete rescue of the Th2 skewing, clearly demonstrating that basophil was promoting the Th2 
bias seen in these mice.  Of particular note, the CD4+ T cells from spleens of Lyn-/- mice 
constitutively produced only Th2 cytokines, no IFN-γ was detected in these cells.  Moreover, 
Lyn-/- mice failed to effectively fight an infection with the prototypic Th1 parasite Toxoplasma 
Gondii, which requires IFN-γ production for survival from infection.  Measurement of IFN-γ 
levels demonstrated that Lyn-/- mice did not mount a normal Th1 response.  However, it should 
be noted that in vitro restimulation of CD4+ T cells from Lyn-/- mice with PMA and ionomycin 
caused increased IFN-γ production (as well as IL-4 and IL-13) when compared to WT cells [30].  
This suggests that T cells from these mice are primed by the Lyn-/- environment in a manner that 
can result in potent Th1 or Th2 responses. 
The mechanism by which basophils can induce the IL-4 production necessary for the 
potent Th2 skewing of Lyn-/- mice was explored in some detail.  In mast cells, the 
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hyperresponsiveness observed upon Lyn deficiency is, at least in part, through increased Fyn 
kinase activity [43,45,54] and the loss of SHIP activity [54].  As these molecules regulate the 
activity or the amount of product, respectively, of phosphatidylinositide 3-OH kinase (PI3K), a 
kinase that generates phosphatidylinositide 3,4,5-trisphosphate (PIP3), loss of regulatory control 
on PIP3 production in these cells causes their hyperresponsiveness [55].   However, whether this 
mechanism also provided the underpinnings of the hyperresponsiveness of basophils was not 
known.  Studies to address the role of PI3K in basophils revealed that its activity was necessary 
for the increased expression of GATA3 (a transcription factor known to regulate IL-4 production 
in T cells) in Lyn-/- basophils.  Lyn-/- basophils showed a marked increase in GATA3 expression 
relative to their WT counterparts and this (as well as IL-4 production) was inhibited by 
pharmacological inhibition of PI3K activity [30].  In addition, basophils from Fyn-/- mice failed 
to upregulate GATA3 and were impaired in the production of IL-4.  Thus, the Th2 skewing was 
linked to a Fyn/PI3K-dependent increased induction of GATA3 in Lyn-/- basophils. 
The clear dominance of a Th2 environment in Lyn-/- mice and the late life development of 
a spontaneous lupus-like disease provided a good model system to explore the relationship 
between the Th2 environment and the development of a lupus-like phenotype. 
 
Is there a link between the Th2 environment and development of a lupus-like phenotype? 
Removing IgE or IL-4 genes in the context of the Lyn-/- background led to the reversion of the 
Th2 bias seen in Lyn-/- mice.  These double deficient mice provided a model to ask the question 
of whether the Th2 bias was linked to the development of a lupus-like disease.  Aging of such 
mice for greater than 35 weeks along with Lyn-/- mice revealed that the penetrance of disease was 
almost 100% in the latter mice whereas IgE/Lyn or IL-4/Lyn double deficient mice showed little 
signs of kidney disease.  Indeed, the double deficient mice had a greater than 50% reduction in 
autoantibody titers and immune complex deposition in the glomeruli was markedly reduced with 
normal albumin/creatinine levels in the urine.  Analysis of the extent of glomerular nephritis by 
scoring immune infiltrates, mesangial proliferation, morphology of the glomeruli, and other 
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parameters revealed little evidence of kidney disease and damage.  Thus, it was evident that 
inhibiting the Th2 skewing of Lyn-/- mice by depletion of IL-4 or IgE greatly reduced 
autoantibody production and ablated the development of overt kidney disease and damage [12].  
This unexpected result led us to question if basophils were contributing to the development of 
the lupus-like phenotype seen in Lyn-/- mice. 
 
Basophils and autoreactive IgE in the development of lupus.  
Evidence from the Lyn-/- mouse model  
At the time of this work basophil deficient mice were not available.  Thus, once again, we 
depleted basophils with the anti-FcεRIα (MAR-1 antibody) and found that basophils were 
needed to maintain high autoantibody (IgM, IgG, IgA) titers in the circulation of Lyn-/- mice.  
Depletion of basophils caused a marked decrease in anti-ANA IgG and anti-dsDNA IgG 
antibodies within 6 days post-treatment.  This was somewhat unexpected given the long half-life 
of antibodies in the blood, although immune complexes are cleared more rapidly than normal 
immunoglobulins by binding to cells.  Nonetheless, we hypothesized that the role of basophils 
might extend to the support of plasma cell survival and function and in this manner could more 
rapidly influence control on antibody levels.  This view was supported by the recent finding of 
others [26] showing that basophils contribute to humoral memory responses through their 
production of IL-4 and IL-6.  Within 6 days of basophil depletion, the numbers of plasma cells 
(likely plasmablasts) in the spleen of Lyn-/- mice decreased by greater than 50%.  These findings 
showed the direct involvement of basophils in supporting plasma cells in the spleen of Lyn-/- 
mice that can produce autoantibodies [12].  Our findings that basophil support plasma cell 
survival and antibody production has recently been confirmed by others [34].   
Given that Lyn-/- mice had a peripheral basophilia and produced high levels of IL-4, IL-6 
and TSLP, we asked: How do these basophils become activated?  Our previous findings 
demonstrated that Lyn-/- basophils were hyper-reactive to stimulation via FcεRI.  Moreover, 
given that IL-4/Lyn and IgE/Lyn double deficient mice (which are not Th2 skewed) did not  
Running Title: Basophils in Lupus. 
Charles & Rivera   
 12
produce high levels of auto-reactive antibodies or CIC’s to induce kidney disease, we reasoned 
that in this model, IgE and the FcεRI were involved in the activation of the basophils and 
pathogenesis of disease.  In part our reasoning was based on the prior description of the presence 
of autoreactive IgE in the circulation of SLE patients [18,20].  Analysis of Lyn-/- mice for 
autoreactive IgE in the circulation revealed the presence of anti-dsDNA and anti-ANA 
autoantibodies of the IgE isotype.   Compared to WT mice, large amounts of anti-ANA and anti-
dsDNA IgE were found in the sera of Lyn-/- mice.  Moreover, the presence of large amounts of 
CIC containing IgE was also detected by western blot.  We then tested if IgE-containing immune 
complexes could induce IL-4 production from WT and Lyn-/- basophils and found that indeed 
these immune complexes could effectively activate both WT and Lyn-/- basophils, with the latter 
producing higher amounts of IL-4.  In contrast, immune complexes that contained only IgG 
failed to induce IL-4 production from basophils of both genotypes.  These findings provided a 
mechanistic explanation on how basophils might be continuously activated in the periphery of 
Lyn-/- mice.   
The support of autoantibody production would require that activated basophils be in the 
appropriate environment to support T and/or B cell function.  This would require their migration 
to the secondary lymphoid organs.  To assess their ability to migrate to the secondary lymphoid 
organs (such as the lymph nodes and spleen), we measured the levels of CD62L (L-selectin) on 
the surface of basophils from WT and Lyn-/- mice.  CD62L is recognized as a necessary molecule 
for leukocyte rolling and recruitment from blood stream to tissues.  Measurement of CD62L 
expression on Lyn-/- basophils revealed a marked increase in its expression relative to WT 
basophils.  Under normal conditions (in aged WT mice), the numbers of basophils in the lymph 
nodes are very small and difficult to detect.  In contrast, aged Lyn-/- mice had very high numbers 
of basophils in peripheral lymph nodes as well as in the spleen.  This placed the basophil in the 
appropriate environment where it could influence T and B cell function.  However, the question 
as to whether the Lyn-/- basophil expressed the appropriate molecules to interact with T and B 
cells remained to be answered.  Recently, in both mouse and human basophils, it has been 
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described [31-33] that these cells can express molecules of the major histocompatibility complex 
II (MHC-II).  Whereas circulating basophils from Lyn-/- mice expressed low levels of MHC-II 
molecules on their surface, the basophils found in the lymph nodes of these mice were 
expressing high levels of MHC-II.  The antigen being presented by these basophils remains an 
enigma, however, one might speculate that autoantigenic epitopes may well reside on the surface 
of these cells.  Thus, these findings provide evidence that the basophil is capable of antigen 
presentation, since the appropriate expression of MHC-II requires it’s assembly in the context of 
the antigenic peptide epitope [56].  In addition, however, a membrane-bound form of BAFF (B 
cell activating factor) was also detected on the surface of Lyn-/- basophils found in the lymph 
nodes, as has been described for human basophils in other chronic inflammatory diseases [57].  
Interestingly, this was independent of increased BAFF receptor expression suggesting that the 
expressed BAFF was not bound to the receptor.  Thus, these findings show that Lyn-/- basophils 
home to the secondary lymphoid organs and are fully equipped to support T and B cells at these 
sites.  This is consistent with our finding that basophils support plasma cells in the spleen of Lyn-
/-
 mice [12].  Given that such plasmablasts require T cells for their expansion, our data suggests 
that basophils are also providing help to T cells in secondary lymphoid tissues.   
Given the marked impairment of autoantibody production by the depletion of basophils, 
we asked whether the absence of basophils had any bearing on the kidney inflammation of Lyn-/- 
mice during the manifestation of lupus nephritis.  Within 6 days of basophil depletion a marked 
reduction was observed in the pro-inflammatory cytokines (IL-4, IFN-γ, IL-1β, MCP-1, TNF-α 
and IL-6) in the kidneys of these mice [12].  This showed that beyond their role as contributors 
to autoantibody production, the basophil also contributes to the pathogenesis of lupus nephritis 
by promoting inflammation. 
The data obtained through the study of Lyn-/- mice demonstrates that in this model of 
SLE, the Th2 bias is contributing to the pathogenesis of disease.  Perhaps, the best evidence is 
the requirement for IL-4 and IgE for disease manifestation in Lyn-/- mice.  Our findings suggest 
that the basophil and autoreactive IgE’s serve to amplify the role of autoreactive T and B cells in 
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establishing the disease (Figure 1).  This amplification seems to be key in determining the 
threshold of autoantibodies that are necessary to establish disease, presumably because the body 
can no longer effectively remove the high levels of autoantibodies and CIC’s produced once this 
basophil-dependent amplification loop is fully established (Figure 1). 
  
Basophils and autoreactive IgE in human SLE 
While our findings in Lyn-/- mice clearly provide evidence of a Th2 influence in the pathogenesis 
of SLE, the relevance of the findings in this model to human disease must be explored.  Evidence 
for the role of Th1 and Th17 cell subsets in human SLE is considerable [1].  In contrast, evidence 
for Th2 involvement is sparse and is primarily restricted to certain populations of SLE patients 
with more circulating IgE than healthy individuals [18,21].  Interestingly, the increased levels of 
circulating IgE were not associated with an increased incidence of atopic disease in this 
population of patients [18].  This suggested that a Th2 skewing might be seen in certain SLE 
patients.  A more informative finding was the description of autoreactive IgE and IgE containing 
immune complexes in some SLE patients [20].  While described, the role of these autoreactive or 
IgE containing immune complexes in disease was not known.  Thus, we set out to explore 
whether the presence of autoreactive IgE’s (anti-dsDNA and anti-ANA) might be associated with 
different measures of disease activity in SLE patients.  We detected large amounts of 
autoreactive IgE in patient samples relative to healthy controls.  Interestingly, the levels of both 
anti-dsDNA and anti-ANA IgE correlated with disease activity as determined by the SLEDAI 
score of the patients.  Remarkably, patients with active lupus nephritis seemed to show the 
highest levels of anti-dsDNA IgE when compared to patients without kidney involvement [12].  
These findings suggested that like shown in our mouse model, autoreactive IgE’s might play a 
role in the pathogenesis of lupus in humans.   
Whether basophils might be activated in human SLE was subsequently explored.  Blood 
basophils from the same cohort of 42 patients and 40 healthy volunteers were analyzed for their 
activation status.  Unlike mouse basophils, human basophils have known surface markers that 
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are expressed upon their activation, such as CD63, CD203c or CCR3.  Each of these markers 
reflect slightly different activation conditions.  For instance, CD63 expression reflects the 
degranulation of the basophil, since CD63 is a granule membrane protein that becomes expressed 
on the cell surface only after the intracellular granule fuses with the plasma membrane.  In 
contrast, CD203c is expressed when basophils are activated under conditions where they may or 
may not degranulate.  Thus, we used this marker to assay for basophil activation.  Analysis of 
CD203c expression showed that basophils from SLE patients were highly activated.  In addition, 
peripheral basophils from SLE patients expressed higher levels of MHC-II molecules (HLA-DR) 
than the healthy controls, suggesting that their activation could result in basophil communication 
with T and B cells.  
When analyzed for whether basophils could home to the secondary lymphoid organs in 
SLE patients, CD62L levels were found to be increased as compared to healthy controls, 
confirming the ability of these cells to home to these organs and their activated phenotype.  To 
confirm that these cells were present in the lymph nodes and spleen from SLE patients, we 
analyzed several biopsy specimens of these tissues from SLE patients.  In contrast to non-SLE 
biopsies (controls), basophils were found in the lymph nodes and spleens of SLE patients with 
their primary localization in germinal centers, in the middle of the B cell zone and in the 
surrounding T cell zone.  No basophils were detected in control samples.  Thus, basophils were 
shown to be in secondary lymphoid tissues, alike to our observation in Lyn-/- mice.  Given that 
basophils were recruited to secondary lymphoid organs, one might expect that the numbers of 
basophils in the circulation would decrease.  Both the percentage and absolute numbers of 
circulating basophils were reduced in SLE patients.  These findings once again demonstrated that 
the activation of basophils in SLE caused increased expression of cell surface molecules 
(CD203c, CD62L, MHC-II…) that promote the recruitment of basophils to the secondary 
lymphoid organs and may allow their interaction with T and B cells.  Collectively, the studies on 
human SLE patients are consistent with the conclusions from the analysis of Lyn-/- mice.  They 
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support that concept that autoreactive IgE and activated basophils are likely contributors to the 
pathogenesis of SLE (Figure 1). 
   
Basophils and autoreactive IgE as therapeutic target in human SLE 
The aforementioned findings suggest two new putative therapeutic targets in the treatment or 
prevention of lupus nephritis; namely autoreactive IgE and basophils.  The involvement of these 
two factors, in an amplification loop that increases the levels of autoantibodies and CIC, suggests 
that disruption of this loop could have therapeutic benefit.  Nonetheless, there are many poorly 
understood factors for the heterogeneity of disease.  It is still not known what makes the 
difference between an SLE patient that develops active nephritis and one that does not.  When 
looking at SLE patients with lupus nephritis, it is still not understood why some will develop 
class I or class II nephritis (with low severity, with mainly mesangial deposits) and others will 
develop class III or class IV nephritis (with high severity, mesangial deposits, extramembranous 
deposits and vasculitis).  Our findings suggest that it is possible that the presence of level of 
activation of such amplification loops (whether basophil driven or not) might explain some of 
these features; based on the fact that class III and class IV states are correlated with the titers of 
autoantibodies and CIC.  Thus targeting of basophils as one possible cell type for amplification 
of autoantibody production could lead to a beneficial outcome for some patients.  This recent 
clinical trials targeting B cell activation [7] suggests that such approaches may have some 
clinical benefit in SLE.  However, one must be cautious in developing such an approach for the 
basophil as the release of pro-inflammatory mediators (histamine, TNF-α, platelet activating 
factor…) contained in this cell could be an unwanted consequence of its depletion.  In addition, 
one must consider the consequences of depleting a potential immune regulator and a potent 
effector against parasitic infections.  Consideration of such therapeutic strategies requires further 
evaluation of short term and long term depletion of basophils in health and disease.  
Thus, a more tempting therapeutic target might be to inhibit the activation of the basophil 
through depletion of autoreactive IgE.  Depletion of IgE-containing CIC would disrupt the 
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persistent activation of basophils in SLE, blocking the amplification loop, decreasing the 
amounts of circulating autoantibodies.  Depletion of IgE from the circulation is a strategy already 
in use in other diseases, such as allergic asthma.  Omalizumab (Xolair®, Novartis) has shown 
efficacy in treatment of asthma  [58]and allergic rhinitis [59] through blocking the binding of IgE 
to FcεRI.  This monoclonal antibody was raised against the Fc portion of the IgE and binds the 
epitope on the IgE molecule that interacts with the FcεRIα.  Once IgE is bound by this anti-IgE 
antibody, the IgE can no longer bind to the FcεRI.  Thus, such an approach should stop basophil 
activation by IgE-containing CIC in SLE and may lead to interruption of the amplification loop 
described in Figure 1.  Such studies are currently underway and should provide novel insights on 
the role of autoreactive IgE in basophil activation in SLE patients and beyond. 
 
Concluding remarks 
The recent advances in our understanding of the role of basophils in health and disease 
demonstrate that the longed ignored basophil granulocyte has an important immunomodulatory 
role in the immune system.  The findings described herein show that, in some settings, the 
basophil, through its ability to communicate with T and B cells, links the Th2 environment as a 
contributor to the development of an autoimmune disease, like SLE.  It will be of considerable 
interest to explore if this will translate to therapeutic benefit in disease. 
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Figure 1: Basophil and autoreactive IgE amplify autoantbody production in SLE. 
SLE is a consequence of the loss of tolerance promoting autoreactive T and B cells that escape 
from negative selection.  These autoreactive lymphocytes produce large amounts of circulating 
immune complexes (CICs) comprised of aggregated autoreactive antibodies, complement factors 
and autoantigens.  Autoreactive IgGs, IgMs and IgAs comprise the majority of autoantibodies, 
but autoreactive IgE’s also accumulate as CICs reaching a threshold that activates circulating 
blood basophils recruiting these cells to lymphoid organs via upregulation of CD62L on their cell 
surface.  Once recruited to the secondary lymphoid organs, basophils can interact directly with 
autoreactive lymphocytes through upregulation of molecules like MHC-II and membrane bound 
BAFF.  Together with the basophils ability to secrete large amounts of IL-4 (and IL-6), these 
cells can promote plasma cell survival and amplify autoantibody production, leading to the 
disease amplification.  The presence of large amounts of autoantibody promotes the levels of 
pro-inflammatory cytokines found in the target organs, like the kidneys, resulting in uncontrolled 
inflammation and organ damage.  
